12:00 AM
 | 
Oct 02, 2006
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alagebrium: Phase II start

Next year, ALT will begin a double-blind, placebo-controlled, U.S. Phase II trial to improve cardiac compliance and...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >